Angiotensin II mediates uterine vasoconstriction through alpha-stimulation.
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000804:Angiotensin II / Q000008:administration & dosage / Q000502:physiology*; D047228:Angiotensin II Type 1 Receptor Blockers; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006439:Hemodynamics; D007275:Injections, Intravenous; D010656:Phenylephrine / Q000008:administration & dosage; D011247:Pregnancy; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D012756:Sheep; D014599:Uterus / Q000098:blood supply*; D014655:Vascular Resistance / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology*
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D011942:Receptors, Adrenergic, alpha; D000804:Angiotensin II; D010656:Phenylephrine